Veno‐occlusive disease risk in pediatric patients with acute myeloid leukemia treated with gemtuzumab ozogamicin before allogeneic hematopoietic cell transplantation
Abstract
Gemtuzumab ozogamicin (GO) administered before allogeneic hematopoietic cell transplantation (alloHCT) has been linked to an increased risk of hepatic veno‐occlusive disease/sinusoidal obstruction syndrome (VOD/SOS).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 19, 2021
- Source ID
- 10.1002/pbc.29067
Entities
People
- Andrew St. Martin
- Caroline J. Hoang
- Christine Duncan
- Deborah Chirnomas
- Fausto R. Loberiza Jr.
- Mei‐jie Zhang
- Patricia Steinert
- Wael Saber
- Waleska S. Pérez
Organizations
- Dana–Farber Cancer Institute
- Health Resources and Services Administration
- Medical College of Wisconsin
- Office of Naval Research
- Pfizer